The DOI matches its Crossref record; 193 of the 193 references it cites were found in a registry or an index.
Myeloid-Derived Suppressor Cells
Open accessAbstract
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that suppress innate and adaptive immunity. MDSCs are present in many disease settings; however, in cancer, they are a major obstacle for both natural antitumor immunity and immunotherapy. Tumor and host cells in the tumor microenvironment (TME) produce a myriad of pro-inflammatory mediators that activate MDSCs and drive their accumulation and suppressive activity. MDSCs utilize a variety of mechanisms to suppress T cell activation, induce other immune-suppressive cell populations, regulate inflammation in the TME, and promote the switching of the immune system to one that tolerates and enhances tumor growth. Because MDSCs are present in most cancer patients and are potent immune-suppressive cells, MDSCs have been the focus of intense research in recent years. This review describes the history and identification of MDSCs, the role of inflammation and intracellular signaling events governing MDSC accumulation and suppressive activity, immune-suppressive mechanisms utilized by MDSCs, and recent therapeutics that target MDSCs to enhance antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Panka, D. J., Liu, Q., Geissler, A. K., & Mier, J. W. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-17 · Cited by 38
RetractedInflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 1×
“Examples include hepatocellular carcinoma in patients infected with hepatitis B or C viruses (Karin, 2006), and bladder and colon cancer in individuals infected with Schistosoma or Bacteroides, respectively (Mostafa, Sheweita, & O’Connor, 1999; Wu et al., 2009).”
BackgroundPolarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“VEGF has been shown to be released from the extracellular matrix by MMP9, a matrix degrading enzyme (Bergers et al., 2000).”
BackgroundNoman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Cited by
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K., & Heymach, J. V. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1366 · Cited by 481
Steggerda, S. M., Bennett, M. K., Chen, J., Emberley, E., Huang, T., Janes, J. R., Li, W., MacKinnon, A. L., Makkouk, A., Marguier, G., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0308-4 · Cited by 476
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 443
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
Evaluating intrinsic and non-intrinsic cancer risk factors
Wu, S., Zhu, W., Thompson, P., & Hannun, Y. A. (2018) · Nature Communications · doi:10.1038/s41467-018-05467-z · Cited by 437
Wang, J., Li, D., Cang, H., & Guo, B. (2019) · Cancer Medicine · doi:10.1002/cam4.2327 · Cited by 349
Al-Khami, A. A., Zheng, L., Del Valle, L., Hossain, F., Wyczechowska, D., Zabaleta, J., Sanchez, M. D., Dean, M. J., Rodriguez, P. C., & Ochoa, A. C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1344804 · Cited by 346
Emerging Opportunities and Challenges in Cancer Immunotherapy
Whiteside, T. L., Demaria, S., Rodriguez-Ruiz, M. E., Zarour, H. M., & Melero, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0049 · Cited by 317
Zhang, X., Zeng, Y., Qu, Q., Zhu, J., Liu, Z., Ning, W., Zeng, H., Zhang, N., Du, W., Chen, C., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1161-7 · Cited by 316
Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma
Elmusrati, A., Wang, J., & Wang, C.-Y. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00131-7 · Cited by 312
miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
Givel, A.-M., Kieffer, Y., Scholer-Dahirel, A., Sirven, P., Cardon, M., Pelon, F., Magagna, I., Gentric, G., Costa, A., Bonneau, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03348-z · Cited by 295
Mechanisms and dynamics of T cell-mediated cytotoxicity in vivo
Halle, S., Halle, O., & Förster, R. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.04.002 · Cited by 302
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Enblad, G., Karlsson, H., Gammelgård, G., Wenthe, J., Lövgren, T., Amini, R. M., Wikstrom, K. I., Essand, M., Savoldo, B., Hallböök, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0426 · Cited by 269
Li, L., Wang, L., Li, J., Fan, Z., Yang, L., Zhang, Z., Zhang, C., Yue, D., Qin, G., Zhang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2460 · Cited by 266
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Stultz, J., & Fong, L. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00340-5 · Cited by 242
Azzaoui, I., Uhel, F., Rossille, D., Pangault, C., Dulong, J., Le Priol, J., Lamy, T., Houot, R., Le Gouill, S., Cartron, G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662783 · Cited by 168
Jia, Y., Li, X., Jiang, T., Zhao, S., Zhao, C., Zhang, L., Liu, X., Shi, J., Qiao, M., Luo, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32191 · Cited by 164
“It has been proposed that the presence of a large number of apoptotic tumors enhances antigen-presenting ability in dendritic cells as well as T-cell response.38 However, activation of immunosuppressive cells accumulated in tumors, such as MDSCs, Tregs, and type 2-polarized macrophages inhibits the anti-tumor immune r…”
BackgroundVetsika, E.-K., Koukos, A., & Kotsakis, A. (2019) · Cells · doi:10.3390/cells8121647 · Cited by 125
Geis-Asteggiante, L., Belew, A. T., Clements, V. K., Edwards, N. J., Ostrand-Rosenberg, S., El-Sayed, N. M., & Fenselau, C. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00646 · Cited by 104
Self-citationJin, Y., An, X., Mao, B., Sun, R., Kumari, R., Chen, X., Shan, Y., Zang, M., Xu, L., Muntel, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07153-z · Cited by 73
Garton, A. J., Seibel, S., Lopresti-Morrow, L., Crew, L., Janson, N., Mandiyan, S., Trombetta, E. S., Pankratz, S., LaVallee, T. M., & Gedrich, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0676 · Cited by 32
Metadata
- Venue
- Advances in Cancer Research
- Publisher
- Elsevier
- Published
- 2015
- Volume
- 128
- Pages
- 95-139
- ISSN
- 0065-230X (ISSN-L)
- OpenAlex
- W210558271
- Cited by
- 482
- References
- 193
- FWCI
- 120.29
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.